MAPT and Alzheimer disease: We distinguish three major categories of biomarkers in AD: (1) diagnostic markers—PET imaging and CSF analysis for Aβ and Tau; (2) blood markers—protein and miRNA biomarkers analyzed in the whole blood, plasma or serum; and (3) ocular markers—the least invasive methods based on the identification of AD-associated changes in the retina.